These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38297484)

  • 1. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
    Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
    Tomlinson BK; Gallogly MM; Kane DM; Metheny L; Lazarus HM; William BM; Craig MD; Levis MJ; Cooper BW
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):226-233.e1. PubMed ID: 32085993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
    Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
    Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
    Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
    Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
    Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
    Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin approved for FLT3-mutated AML.
    Levis M
    Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.